Search results
Showing 7111 to 7125 of 8224 results
In February 2023, NICE withdrew this guidance following a review. The original guidance published in 2013 and recommended the use of WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension. However the guidance review in 2022 recommended it be withdrawn because it was determined that: The existing medical technologies guidance was considered along with other interventions in the update of NICE's guideline on atrial fibrillation. See evidence review A and evidence review B providing the best advice to the NHS about its use. As evident in NICE's guideline on atrial fibrillation, the evidence base and experts’ advice, the landscape for opportunistically detecting atrial fibrillation in primary care has changed significantly since the original guidance, with a wider range of devices for detecting atrial fibrillation now available.
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)
This guidance has been updated and replaced by NICE technology appraisal guidance 527.
This guidance has been updated and replaced by NICE interventional procedures guidance 809.
This guidance has been updated and replaced by NICE interventional procedures guidance 809.
This guidance has been withdrawn because the simple discount patient access scheme for QuiremSpheres has been withdrawn.
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or recently pregnant people (NG255).
This guidance has been updated and replaced by NICE technology appraisal guidance 1110.
November 2025: We have withdrawn this quality standard following the launch of new NICE guidelines on suspected sepsis in people aged 16 or over, suspected sepsis in under 16s and suspected sepsis in pregnant or recently pregnant people. This quality standard is now partially replaced by NICE's quality standard on suspected sepsis in over 16s. Quality standards for sepsis in people under 16 and for people who are or have recently been pregnant will publish when paediatric and maternity early warning score tools are reviewed for the next update to the NICE guidelines in 2026. For any queries, please contact qualitystandards@nice.org.uk.
This advice has been updated and replaced by NICE medical technologies guidance 42.
VitalPAC for assessing vital signs of patients in hospital (MIB79)
This advice has been updated and replaced by NICE medtech innovation briefing 205.
This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.
Lutonix drug-coated balloon for peripheral arterial disease (MIB72)
NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.
We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See NICE review 1 on DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
Discontinued Reference number: GID-TA10065
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066